MICROBIOMA : UNA TERAPIA PER LA POUCHITE E LA COLITE ULCEROSA. UNA BUONA REVISIONE

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis Jean-Frédéric LeBlanc et al. Abstract The gut microbiome has been implicated in a range of diseases and there is a rapidly growing understanding of this ecosystem’s importance in inflammatory bowel disease. We are yet to identify a single microbe that causes either ulcerative colitis (UC)…

MA QUALE EVIDENZA C’E’ IN FAVORE DELLA CHIRURGIA ROBOTICA ADDOMINALE ? UNA REVISIONE SISTEMATICA

The Evidence Behind Robot-Assisted Abdominopelvic Surgery. A Systematic Review Naila H. Dhanani, eta  al. Background: Use of robot-assisted surgery has increased dramatically since its advent in the 1980s, and nearly all surgical subspecialties have adopted it. However, whether it has advantages compared with laparoscopy or open surgery is unknown. Purpose: To assess the quality of…

MODULAZIONE DEL MICROBIOTA ED ENCEFALOPATIA. UNA REVIEW SULLE NUOVE TERAPIE DAL GRUPPO DI BAJAI

Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment Ramzi Hassouneh and Jasmohan S. Bajaj Simple Summary: Treatment of advanced liver disease and its complications continue to be a challenge due to the complexity of this illness. In recent years, the gut microbiome has been recognized to play a…

FDA AUTORIZZA IN EMERGENZA L’USO DI TOCILIZUMAB NEI PAZIENTI OSPEDALIZZATI PER COVID-19

Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra (tocilizumab) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation,…

GLI ANTAGONISTI DELLA IL-6 RIDUCONO LA MORTALITA’ DA COVID-19 NEGLI OSPEDALIZZATI: UNA META-ANALISI DAL GRUPPO WHO

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. A Meta-analysis The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Key PointsQuestion  Is administration of IL-6 antagonists associated with 28-day all-cause mortality in patients hospitalized for COVID-19? Findings  This prospective meta-analysis of 27 randomized trials included 10 930 patients, of whom 2565…

POVERA EBM: I DUBBI SULL’ULTIMO TRIAL ANTI COVID-19. RIDUZIONE DELLA MORTALITA’ DEL 77% ? DA “SCIENCE”

‘Too good to be true’: Doubts swirl around trial that saw 77% reduction in COVID-19 mortality Robert F. Service Science’s COVID-19 reporting is supported by the Heising-Simons Foundation. It would be the best news by far in COVID-19 treatment: According to a preprint published on 22 June, an experimental prostate cancer drug named proxalutamide reduced deaths…